Our data indicated that USP13 is a potential independent biomarker for predicting the prognosis of PCa patients and that targeting USP13 might suppress the activity of AR signaling and improve the effectiveness of DDR inhibitors and ICB against CRPC. The gene discussed is AR; the disease is posterior cortical atrophy.